明早8:00开始！上科大生命学院-《细胞》研讨会｜基因组技术助力在体单细胞及组织生物学研究

▌个人简历：

Aviv Regev 是Genentech科研发展部的负责人。在加入Genentech之前，她是麻省理工学院生物学教授和霍华德休斯医学研究所的研究员。她是人类细胞图谱的联合创始人。她的实验室开创了单细胞基因组学的基础性实验和计算方法，致力于更好地了解细胞和组织在健康和疾病中的功能，包括自身免疫性疾病、炎症和癌症。她是美国国家科学院和国家医学院的成员，也是国际计算生物学会的会员。她是多个奖项和荣誉的获得者，包括国际计算生物学会的奥弗顿奖和创新者奖、保罗马克斯奖、卢里生物医学科学奖和庆应医学奖。

▌英文简历：

Aviv Regev is the head of Genentech Research and Early Development. Prior to Genentech, Regev served as Chair of the Faculty and Core Member at the Broad Institute of MIT and Harvard, and as Professor of Biology at MIT and Investigator at the Howard Hughes Medical Institute. She is a founding co-chair of the Human Cell Atlas.  Regev is a leader in deciphering molecular circuits that govern cells, tissues and organs in health and their malfunction in disease. Her lab has pioneered foundational experimental and computational methods in single-cell genomics, working toward greater understanding of the function of cells and tissues in health and disease, including autoimmune disease, inflammation and cancer. She is a member of the National Academy of Sciences and National Academy of Medicine, and a Fellow of the International Society of Computational Biology. She is a recipient of multiple prizes and honors, including the Overton and Innovator Prizes from the International Society of Computational Biology, the Paul Marks Prize, the Lurie Prize in Biomedical Sciences, and the Keio Medical Science Prize.

▌个人简历：

郭国骥教授是浙江大学血液学研究所副所长、干细胞学会副理事长。2010年在新加坡国立大学获得博士学位，后赴哈佛大学医学院进行博士后培养。2014年被浙江大学聘为终身教授。郭国骥教授对开发新的单细胞分析技术和应用这些技术研究干细胞生物学很感兴趣。

▌英文简历：

Professor Guoji Guo is the deputy director for Institute of hematology and the deputy chair of Stem Cell Society at Zhejiang University. He obtained his Ph.D at National University of Singapore in 2010, and then moved to Harvard Medical School for postdoc training. In 2014, he was recruited and directly tenured at Zhejiang University. Professor Guoji Guo is interested in developing new single cell analysis technologies and applying these technologies to investigate stem cell biology. 

▌内容摘要：

Despite extensive efforts to sequence different genomes, genetic models to interpret gene regulation and cell fate decisions are lacking for most species. Here, we mapped single-cell landscapes covering six representative metazoan species using Microwell-seq. We determined the cell type composition and studied gene regulatory network across species. We developed a deep learning–based model, NvWA, to predict expression landscapes and decipher regulatory elements at the single-cell level. Although entirely derived from the genome sequences without introducing any epigenetics information, NvWA recognizes global regulatory signals that are comparable to experimental data. We prioritized important regulatory relationships and decipher principles of cell-type evolution. Our work provides a valuable resource for studying regulatory language in diverse biological systems.

▌个人简历：

Winslow 博士在加拿大长大，在加拿大维多利亚大学获得本科学位。他在斯坦福大学攻读免疫学博士学位，然后在麻省理工学院进行博士后培训。

Winslow 博士的研究重点是了解驱动癌症发展、进展、转移和治疗反应的机制。他开发了体内小鼠模型，以实现癌细胞的分离和基因组特征，并利用这些模型来帮助我们理解癌症的发生、生长和发展。这些研究的重点是揭示导致三种转移性最强和最致命的癌症类型的发展和进展的分子力量：肺腺癌、小细胞肺癌和胰腺癌。他还为开发新的癌症模型方法做出了贡献，这些方法能够快速和定量地分析致癌的遗传因素。他的实验室整合了体细胞CRISPR/Cas9介导的基因组编辑方法。通过纳入越来越多的定量方法，Winslow 博士的工作正在发现支配不同肿瘤基因型的肿瘤启动、生长和进展的一般规则。

▌英文简历：

Dr. Winslow grew up in Canada and received his undergraduate degree from the University of Victoria, Canada. He did his PhD studies in Immunology working with Dr. Jerry Crabtree at Stanford University before pursuing is postdoctoral training with Dr. Tyler Jacks at MIT. 

Dr. Winslow’s research focuses on understanding the mechanisms that drive cancer development, progression, metastasis, and therapy response. He has developed in vivo mouse models to enable the isolation and genomic characterization of cancer cell and used these models to contribute to our understanding cancer initiation, growth, and progression. These studies have focused on uncovering the molecular forces that contribute to the development and progression of three of the most metastatic and deadly cancer type: lung adenocarcinoma, small cell lung cancer, and pancreatic cancer. He has also contributed to the development of novel cancer modeling approaches that enable rapid and quantitative analyses of the genetic drivers of carcinogenesis. His laboratory has generated methods for somatic CRISPR/Cas9-mediated genome editing and used these models to induce both gain- and loss-of-function alterations in somatic cells in vivo. By incorporating increasingly quantitative methods and powerful in vivo methods, Dr. Winslow’s work is uncovering general rules that govern tumor initation, growth and progression across diverse tumor genotypes.

▌个人简历：

陈斯迪博士于2015年加入耶鲁大学教师队伍，任职于遗传学系、系统生物学研究所和耶鲁大学癌症中心。他的研究重点是提供对生物系统的全面了解和开发新的突破性治疗方法。他的主要愿景是开发下一代技术并将其转化为有效和安全的治疗方法。通过结合两个新兴领域，陈博士创新了 "基因编辑用于免疫治疗，并作为免疫治疗 "的概念。他首次进行了体内CRISPR筛选，并开发了MAEGI作为一种新型的免疫基因治疗概念。陈博士在基因编辑、基因筛选、肿瘤建模、癌症免疫治疗和细胞治疗方面有多项专利。陈博士获得了许多国内和国际奖项，包括：Pershing Square Sohn Prize, DoD Era of Hope Scholar, NIH Director’s New Innovator Award,  Blavatnik Innovator Award, Yale Faculty Innovation Award, Yale Cancer Center Basic Science Research Prize, AACR NextGen Award for Transformative Cancer Research, Ludwig Foundation Award, Damon Runyon Cancer Research Fellow, Dale Frey Award for Breakthrough Scientists, TMKF Innovative/Translation Cancer Research Award, BCA Exceptional Research Grant Award, MRA Young Investigator Award, V Scholar, Bohmfalk Scholar, Ludwig Family Foundation Award, St. Baldrick’s Foundation Award, CRI Clinic & Laboratory Integration Program (CLIP), MIT Technology Review Top 35 Innovators (Regional), and Sontag Foundation Distinguished Scientist Award.

▌英文简历：

Sidi Chen joined the Yale Faculty in 2015 in the Department of Genetics, Systems Biology Institute, and Yale Cancer Center. His research focuses on providing a global understanding of biological systems and development of novel breakthrough therapeutics.  His major vision is to develop next-generation technologies and turn them into effective and safe therapeutics. By intersecting two emerging fields, Dr. Chen innovated the concept “gene editing for, of, and as immunotherapy”. He performed the first in vivo CRISPR screen, and developed MAEGI as a novel immune gene therapy concept. Dr. Chen is named as inventor/co-inventor on >25 patents or patent applications on gene editing, genetic screening, tumor modeling, cancer immunotherapy, and cell therapy. His science has formed the bases for two venture/pharma-backed biotech startups for the development of immunotherapy or cell therapies. My lab currently consists of a team of scientists, students, staffs, trainees. To date, 8 of his previous trainees hold faculty positions in various institutions. 

Dr. Chen received a number of national and international awards including the Pershing Square Sohn Prize, DoD Era of Hope Scholar, NIH Director’s New Innovator Award,  Blavatnik Innovator Award, Yale Faculty Innovation Award, Yale Cancer Center Basic Science Research Prize, AACR NextGen Award for Transformative Cancer Research, Ludwig Foundation Award, Damon Runyon Cancer Research Fellow, Dale Frey Award for Breakthrough Scientists, TMKF Innovative/Translation Cancer Research Award, BCA Exceptional Research Grant Award, MRA Young Investigator Award, V Scholar, Bohmfalk Scholar, Ludwig Family Foundation Award, St. Baldrick’s Foundation Award, CRI Clinic & Laboratory Integration Program (CLIP), MIT Technology Review Top 35 Innovators (Regional), and Sontag Foundation Distinguished Scientist Award.

▌内容摘要：

The overall theme “gene editing for, of, and as immunotherapy” will be discussed. With “gene editing for immunotherapy”, we develop high-throughput CRISPR screening technologies for the discovery of immunotherapy targets. With “gene editing of immunotherapy”, we directly perform gene editing of next-generation therapeutic immune cells such as CAR-Ts to generate better therapeutic cells. With “gene editing as immunotherapy”, we harness gene editing itself directly as novel immunotherapy modalities by re-directing the genetic manipulations towards immune modulation.

▌个人简历：

迟洪波博士在罗切斯特大学获得博士学位，并在耶鲁大学医学院跟随Richard Flavell博士进行博士后培训。2007年，他在圣犹达儿童研究医院开始了他的独立研究项目，目前他是该医院免疫学系教授和 Robert G. Webster 免疫学教授。他的研究重点是免疫信号和代谢的机制，特别是mTOR和其他信号通路如何与T细胞命运的关键决定因素和树突状细胞生物学中的代谢程序相互作用。在这些工作中，他的实验室发现了mTOR信号、代谢和自噬在效应性和调节性T细胞的分化和功能、T细胞静止和抗原触发的退出静止的控制以及自身免疫性、感染性和恶性疾病的调节中的关键重要性。最近，他的实验室应用系统生物学和免疫学方法，如蛋白质组学、代谢组学、单细胞RNA测序（scRNA-Seq）、CRISPR筛选和综合网络分析，重建代谢信号回路，确定癌症和其他免疫介导疾病的新治疗目标。他的工作受到高度重视并被广泛引用，他在2020年和2021年的高被引研究人员名单上占有一席之地。他最近获得了AID R37优秀奖以及NCI杰出研究员奖。

▌英文简历：

Hongbo Chi, Ph.D. received his Ph.D. from the University of Rochester, and his postdoctoral training with Dr. Richard Flavell from Yale University School of Medicine. In 2007, he started his independent research program at St. Jude Children's Research Hospital, where he is currently a member (professor) in the Department of Immunology, and Robert G. Webster Endowed Chair in Immunology. His research focuses on mechanisms of immune signaling and metabolism, in particular how mTOR and other signaling pathways interplay with metabolic programs in T cell fate decisions and dendritic cell biology. Among the highlights of the work, his laboratory has discovered the critical importance of mTOR signaling, metabolism and autophagy in the differentiation and function of effector and regulatory T cells, the control of T cell quiescence and antigen-triggered exit from quiescence, and the regulation of autoimmune, infectious and malignant diseases. More recently, his laboratory applies systems biology and immunology approaches, such as proteomics, metabolomics, single cell RNA-sequencing (scRNA-Seq), CRISPR screening and integrative network analysis, to reconstruct metabolic signaling circuits and identify new therapeutic targets in cancer and other immune-mediated diseases. His work is highly regarded and widely referenced, earning him a place on the 2020 and 2021 Highly Cited Researchers lists. He has recently received an NIAID R37 merit award and an NCI outstanding investigator award.

▌个人简历：

Jay Shendure是霍华德休斯医学研究所的研究员，华盛顿大学基因组科学教授。Shendure博士在西雅图的研究小组开创了外显子组测序，并最早应用于孟德尔疾病和自闭症的基因发现层面；癌症和生殖医学的无细胞DNA诊断；大规模并行报告测定，饱和基因组编辑；生物体系追踪，以及单细胞的大规模并行分子分析。Shendure博士是美国人类遗传学会柯特·斯特恩奖（2012年）、美国国家科学院理查德·劳恩斯伯里奖（2019年）和欧洲人类遗传学会Mendel奖（2022年）的获得者，是美国科学促进会（AAAS）和美国国家科学院（NAS）的成员。他担任或曾经担任过美国国立卫生研究院院长、美国精准医疗计划、国家人类基因组研究中心、以及Chan-Zuckerberg计划的顾问。他于2007年获得哈佛大学医学院的医学和博士学位。

▌英文简历：

Jay Shendure is an Investigator of the Howard Hughes Medical Institute, Professor of Genome Sciences at the University of Washington, Director of the Allen Discovery Center for Cell Lineage Tracing, and Scientific Director of the Brotman Baty Institute for Precision Medicine. His 2005 doctoral thesis with George Church included one of the first successful reductions to practice of next generation DNA sequencing. Dr. Shendure's research group in Seattle pioneered exome sequencing and its earliest applications to gene discovery for Mendelian disorders and autism; cell-free DNA diagnostics for cancer and reproductive medicine; massively parallel reporter assays, saturation genome editing; whole organism lineage tracing, and massively parallel molecular profiling of single cells. Dr. Shendure is the recipient of the Curt Stern Award from the American Society of Human Genetics (2012), the Richard Lounsbery Award from the National Academy of Sciences (2019) and the Mendel Award from the European Society of Human Genetics (2022) and is an elected member of the American Association for the Advancement of Science (AAAS) and the National Academy of Sciences (NAS). He serves or has previously served as an advisor to the NIH Director, the US Precision Medicine Initiative, the National Human Genome Research Institute, the Chan-Zuckerberg Initiative and the Allen Institutes for Cell Science and Immunology. He received his MD and PhD degrees from Harvard Medical School in 2007.

▌个人简历：

刘光慧博士是中国科学院动物研究所的教授。他于2007年在中国科学院生物物理研究所获得博士学位，之后在斯克里普斯研究所和索尔克生物研究所进行了博士后研究。他的研究目标是确定人类干细胞老化的机制及其对人类年龄相关疾病的影响。刘博士实验室的任务是建立一个关于导致或拮抗人类干细胞老化的因素的全球视野，并为 "健康衰老 "的目标开发新的治疗干预措施。刘博士已在《自然》、《科学》、《细胞》等权威杂志上发表了100多篇文章。刘博士一直是国际科学界的积极成员，他是中国老龄化细胞研究学会（CSACR）的主席，Life Medicine的主编，Protein & Cell的副主编，以及Cell Reports和Aging Cell的编委会成员。

▌英文简历：

Guang-Hui Liu is a professor at the Institute of Zoology, Chinese Academy of Sciences. He obtained his Ph.D. from the Institute of Biophysics, Chinese Academy of Sciences in 2007. He performed postdoctoral studies at the Scripps Research Institute and then the Salk Institute for Biological Studies. He aims to identify the mechanisms underlying human stem cell aging and their implications in human age-associated disorders. The mission of Dr. Liu’s laboratory is to establish a global view on the factors contributing to or antagonizing human stem cell aging, and to develop novel therapeutic interventions for the goal of “healthy aging”. Dr. Liu has published over 100 publications in Nature, Science, Cell, etc. prestigious journals. Dr. Liu has been an active member of the international scientific community; he is the president of Chinese Society of Aging Cell Research (CSACR), the chief editor of Life Medicine, the Deputy Editor-in-Chief of Protein & Cell, and an editorial board member of Cell Reports and Aging Cell.   

▌个人简历：

赵可吉博士是国家心脏、肺和血液研究所(NHLBI)系统生物学中心主任，同时也是表观基因组生物学实验室的资深研究员。赵博士于1996年在瑞士日内瓦大学获得博士学位。在加入NHLBI之前，赵博士在加州斯坦福大学Damon Runyon-Walter Winchel癌症研究任博士后研究员。他在2012年被选为美国科学院院士。赵博士的研究重点是染色质的表观遗传调节。他的实验室开发了许多Seq技术，包括ChIP-SAGE、ChIP-Seq、MNase-Seq、单细胞DNase-seq（scDNase-seq）、单细胞MNase-seq、单细胞ChIC-seq、ACT-seq和TrAC-looping。利用这些方法，赵博士的实验室率先在高等真核生物系统中对染色质修饰进行全基因组分析。赵博士的实验室目前正在研究免疫系统中三维核结构和表观基因组细胞异质性的功能和调节。

▌英文简历：

Keji Zhao, Ph.D., is director of the Systems Biology Center at the NHLBI, as well as a senior investigator in the Laboratory of Epigenome Biology. Dr. Zhao received his Ph.D. from University of Geneva, Switzerland in 1996. Prior to joining the NHLBI, Dr. Zhao was a Damon Runyon-Walter Winchel Cancer Research Postdoctoral Fellow at Stanford University, Calif. He was elected to the rank of AAAS Fellow in 2012. Dr. Zhao’s research focuses on the epigenetic regulation of chromatin.  His laboratory developed many -Seq techniques, including ChIP-SAGE, ChIP-Seq, MNase-Seq, single-cell DNase-seq (scDNase-seq), single-cell MNase-seq, single-cell ChIC-seq, ACT-seq, and TrAC-looping. Using these approaches, Dr. Zhao’s lab pioneered whole-genome analyses of chromatin modifications in higher eukaryotic systems. Dr. Zhao’s laboratory is currently investigating the function and regulation of three-dimensional nuclear structure and epigenomic cellular heterogeneity in the immune system. 

▌个人简历：

汤富酬，北京大学生命科学学院BIOPIC中心教授，北京未来基因诊断高精尖创新中心副主任。主要从事人类早期胚胎以及生殖系细胞发育以及癌症的单细胞功能基因组学研究。在国际上率先系统发展了单细胞功能基因组学研究体系，开启了单细胞转录组测序时代（发展了世界上第一个单细胞转录组测序技术（2009），第一个单细胞DNA甲基化组测序技术（2013），第一个单细胞多组学测序技术（scTrio-seq, 2016），第一个单细胞表观基因组多组学测序技术（scCOOL-seq, 2017））第一个高精度单细胞转录组单分子测序技术（SCAN-seq，2020），第一个单细胞基因组单分子测序技术（SMOOTH-seq，2021））。在此基础上，发现了人类生殖系细胞发育过程中基因表达网络的多项重要表观遗传学调控机理。以通讯（或者共同通讯）作者身份在Cell (2013, 2015, 2020)，Nature (2014, 2016, 2018, 2019)，Science (2016, 2018)，Cell Research (2020, 2021, 2022)，Cell Stem Cell (2014, 2017a,b,c, 2018, 2019), Nature Cell Biology (2018a,b), Nature Genetics (2018), Genome research (2013), Gut (2020), Cancer Cell (2020)等期刊发表论文70余篇。其中多项研究工作获评2014年度和2015年度中国科学十大进展，以及2015年度和2019年度中国生命科学领域十大进展。目前为Cell Stem Cell, Cell Research, Protein & Cell, Genome Biology, Genomics Proteomics & Bioinformatics, Precision Clinical Medicine, Open Biology等学术期刊编委。多次受邀参加AGBT (Advances in Genome Biology & Technology)、ISSCR (International Society for Stem Cell Research)、ICHG (International Congress of Human Genetics)、Gordon Conferences (Epigenetics series, Germ cell development series, Cancer series)、HCA (Human Cell Atlas)等国际会议并作受邀报告。

▌英文简历：

Fuchou Tang is a full professor at BIOPIC, College of Life Sciences, Peking University. He is also Associate Director of Beijing Advanced Innovation Center for Genomics (ICG). His lab focuses on the epigenetic regulation of gene expression network during human early embryonic development and germline development. His lab pioneered the single cell sequencing field and has systematically developed a serial of single cell functional genomic sequencing technologies. His work has been cited for more than 14,000 times. He has been invited to give presentations at AGBT, ISSCR, ICHG, Gordon Conference, HCA. He is editorial board members of Cell Stem Cell, Cell Research, Protein & Cell, Genome Biology, Genomics Proteomics & Bioinformatics, Precision Clinical Medicine, Open Biology.

▌个人简历：

徐讯，研究员，博士生导师。现任深圳华大生命科学研究院院长，国际标准化组织/生物技术委员会副主席（ISO/TC276），ISBER (国际生物及环境样本库协会)中国区主席、世界经济论坛未来理事会委员、全国生物样本标准化委员会（SAC/TC559）专家委员。

研究方向包括基因测序仪及相关技术开发、单细胞测序技术、时空组测序技术以及测序技术在疾病和农业领域的转化应用研究等。目前已发表在包括《自然》、《科学》、《细胞》等国际顶级科学杂志在内的SCI收录论文300余篇，连续七年入选科睿唯安“高被引科学家”名单，获授权发明专利48项。主持或参与多项重大项目，包括国家863测序仪开发项目、发改委产业集聚项目、国家重点研发计划等。曾获“科技部大挑战青年科学家”、“鹏城杰出人才奖”、“广东省科学技术奖”一等奖、“教育部自然科学奖”二等奖，广东省和深圳市“最美科技工作者”、第十四届谈家桢“生命科学产业化奖”，入选国家百千万人才工程“有突出贡献中青年专家”。

▌英文简历：

Dr. Xun Xu now serve as the head of BGI Research. He obtained Bachelor in Biology from Wuhan University and Ph.D. in Genetics from Chinese Academy of Science. His research focuses on the sequencer, single-cell sequencing, and Stereo-seq technologies. He build the team and successfully developed the BGIseq sequencer platform. He is also the one of the pioneer in single cell sequencing technology, developing the single cell exome sequencing in 2010, later the C4 single cell technology in 2018, and recently the high definition spatially resolved transcripts technology, the Stereo-seq in 2020. 

▌个人简历：

池天，上海科技大学生命科学与技术学院终身正教授，耶鲁大学客座教授，基金委和科技部资深外专。复旦大学学士，加州大学洛杉矶分校博士，斯坦福大学博士后。2003年始任耶鲁大学免疫生物学系tenure-track faculty；2015年加盟上海科技大学，任生命学院正教授兼耶鲁大学客座教授。科研总目标是通过技术创新来解码和操纵基因功能，以最终造福病人。围绕这一目标，在免疫学、表观遗传学和生物技术领域取得了一系列成果，以通讯或第一作者身份发表论文30多篇，其中大多见于重要刊物包括Cell, Nature (2x), Immunity, Nature communications (2x), EMBO (3x), PNAS (2x) 。主持、参与多项国家级基金，包括美国NIH和中国基金委、科技部基金，申请中国专利4项 （获批2项），其指导、教授的《生物医学导论B》被评为“上海高校一流本科课程”（2021）。

▌英文简历：

Tian Chi obtained Bachelor from Fudan University and PhD from UCLA, and did a Postdoc at Stanford before joining Yale University as a tenure-track faculty. He moved to ShanghaiTech University as a Professor in 2015 while remaining affiliated with Yale as an Adjunct Professor. The overall objective of his research is to decode and manipulate gene function via technological innovations, the ultimate goal being to improve human health. To this end, he made a series of contributions in the areas of immunology, epigenetics, cancer biology and biotechnology, as described in over 30 papers most of them in high-profile journals including Cell, Nature and Immunity.